Anticancer research · 2026
Analysis for IL-22/ IL-22BP Axis and Cell Adhesion Molecules in Advanced Colorectal Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoshida Naohiro, Takamatsu Masayuki, Takaki Kenta, Hisada Kahori, Koga Fumiki, Kikuchi Maako, Shigaki Takahiro, Fujiyoshi Kenji, Ohchi Takafumi, Yoshida Takefumi, Goto Yuichi, Isobe Taro, Mori Naoki, Sakai Hisamune, Sudo Tomoya, Ishibashi Nobuya, Hisaka Toru, Fujita Fumihiko
Аннотация
BACKGROUND/AIM: The mucosal barrier, regulated by cytokines and cell adhesion molecules, is critical to colorectal cancer (CRC) progression. Interleukin (IL)-22 regulates intestinal homeostasis, whereas interleukin-22 binding protein (IL-22BP) functions as its soluble decoy receptor. We aimed to elucidate the clinical significance of IL-22BP and its association with cell adhesion molecules in advanced CRC.
MATERIALS AND METHODS: We retrospectively analyzed data from 178 patients with stage II and III CRC who underwent curative resection. The protein expression of IL-22, IL-22BP, claudin-1, and β-catenin was evaluated using immunohistochemistry on tissue microarrays. We investigated the associations between these markers and clinicopathological features and survival outcomes.
RESULTS: High IL-22BP expression was significantly associated with claudin-1 expression (p=0.043). Patients with low IL-22BP expression demonstrated shorter recurrence-free survival (RFS) (p=0.015) and overall survival (OS) (p=0.037). Multivariate analysis identified low IL-22BP expression as an independent predictor of poor RFS [hazard ratio (HR)=2.265; 95% confidence interval (CI)=1.209-4.242; p=0.011] and OS (HR=2.502; 95%CI=1.174-5.335; p=0.018). In contrast, IL-22 and β-catenin expression was not associated with prognosis.
CONCLUSION: IL-22BP expression correlates with claudin-1 and serves as an independent prognostic biomarker in patients with advanced CRC. Our findings suggest that the IL-22/IL-22BP axis may modulate tight junction integrity to prevent tumor progression, implicating IL-22BP as a potential therapeutic target.
MATERIALS AND METHODS: We retrospectively analyzed data from 178 patients with stage II and III CRC who underwent curative resection. The protein expression of IL-22, IL-22BP, claudin-1, and β-catenin was evaluated using immunohistochemistry on tissue microarrays. We investigated the associations between these markers and clinicopathological features and survival outcomes.
RESULTS: High IL-22BP expression was significantly associated with claudin-1 expression (p=0.043). Patients with low IL-22BP expression demonstrated shorter recurrence-free survival (RFS) (p=0.015) and overall survival (OS) (p=0.037). Multivariate analysis identified low IL-22BP expression as an independent predictor of poor RFS [hazard ratio (HR)=2.265; 95% confidence interval (CI)=1.209-4.242; p=0.011] and OS (HR=2.502; 95%CI=1.174-5.335; p=0.018). In contrast, IL-22 and β-catenin expression was not associated with prognosis.
CONCLUSION: IL-22BP expression correlates with claudin-1 and serves as an independent prognostic biomarker in patients with advanced CRC. Our findings suggest that the IL-22/IL-22BP axis may modulate tight junction integrity to prevent tumor progression, implicating IL-22BP as a potential therapeutic target.